Press Releases for XNPT

Press Releases
XenoPort Reports Second Quarter Financial Results
XenoPort Announces Astellas’ Plans to File an NDA for XP13512 in Japan
XenoPort to Release Second Quarter Financial Results on August 5, 2009
XenoPort Announces Pricing of Public Offering of Common Stock
XenoPort Announces Proposed Public Offering of Common Stock
XenoPort Reports Positive Results from a Phase 2 Trial of Arbaclofen Placarbil in Spinal Cord Injury Patients with Spasticity
XenoPort to Present at the Piper Jaffray Fourth Annual Europe Conference
XenoPort to Present at the Goldman Sachs 30th Annual Global Healthcare Conference
XenoPort Data Presented at Digestive Disease Week Meeting Demonstrates Arbaclofen Placarbil Monotherapy Reduces Heartburn and Regurgitation in GERD Patients Previously Treated with PPIs
XenoPort to Present at the Deutsche Bank 34th Annual Health Care Conference
XenoPort Reports First Quarter Financial Results
Phase II Results for GSK1838262 (XP13512) Reported for Neuropathic Pain Associated with Diabetic Peripheral Neuropathy
XenoPort Announces Election of Co-Promotion Option for Solzira™
XenoPort to Release First Quarter Financial Results on May 5, 2009
XenoPort to Receive $23 Million in Milestone Payments Associated With FDA Acceptance of Solzira NDA
XenoPort to Present at the Cowen Healthcare Conference
Astellas and XenoPort Announce Positive Results from Phase 2 Trial of ASP8825/XP13512 in Japan for Restless Legs Syndrome
XenoPort Reports Fourth Quarter and Year-End 2008 Financial Results
XenoPort to Release Fourth Quarter Financial Results on February 12, 2009
XenoPort Announces 2009 Milestones and Provides Financial Guidance
XenoPort to Present at the 27th Annual J.P. Morgan Healthcare Conference
XenoPort Announces $40 Million Registered Direct Financing
XenoPort Reports Results from a Phase 2 Clinical Trial of XP19986 as a Treatment for the Symptoms of Gastroesophageal Reflux Disease
GSK and XenoPort Announce Plans to Withdraw and Resubmit New Drug Application Requesting Approval of Solzira(TM) for Restless Legs Syndrome
XenoPort to Present at Upcoming Conferences - Nov 6 2008 11:18AM
XenoPort Reports Third Quarter Financial Results
XenoPort to Release Third Quarter Financial Results on November 5, 2008
Zacks Analyst Blog Highlights: Kroger Co., XenoPort, Inc., GlaxoSmithKline Plc., Ltd., Standard Motor Products, Inc. And Vital Images, Inc.
GSK and XenoPort Announce Submission of New Drug Application Requesting FDA Approval of Solzira(TM) for Restless Legs Syndrome
XenoPort to Expand Clinical Development of XP19986
XenoPort to Present at the Morgan Stanley Healthcare Conference - Sep 3 2008 10:37AM
XenoPort Reports Second Quarter Financial Results
XenoPort Appoints Per G. H. Lofberg to Board
XenoPort to Release Second Quarter Financial Results on August 6, 2008
XenoPort Appoints David A. Stamler, M.D., as Chief Medical Officer
XenoPort to Present at the Goldman Sachs Healthcare Conference
XenoPort Appoints Vincent J. Angotti as Chief Commercialization Officer - Jun 2 2008 2:58AM
XenoPort to Release First Quarter Financial Results on May 7, 2008
XenoPort to Present at the Morgan Stanley Healthcare Conference - Jun 2 2008 2:58AM
Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome